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ABSTRACT
Ovarian cancer is the deadliest gynecological malignancy and the fifth leading
cause of cancer death overall. Due to lack of early symptoms, ovarian cancer is most
commonly diagnosed in the distant stages, drastically reducing the 5 year survival rate
from 92% in early stage diagnoses to 29% in advanced stage cases. This large difference
is thought to be linked to the high rate of recurrence and development of drug
resistance to chemotherapeutics in ovarian cancer patients. First-line therapy includes a
combination of tumor resection surgery and chemotherapy regimen including cisplatin,
a DNA-alkylating agent, and paclitaxel, a microtubule stabilization agent. However,
treatment becomes more complex upon recurrence due to the development of drug
resistance. Drug resistance has been linked to many mechanisms, including efflux
transporters, dysregulation of apoptosis, autophagy, cancer stem cells, epigenetics, and
the epithelial-mesenchymal transition. Due to the wide variety of mechanisms involved
in resistance, developing and choosing effective therapies is extremely complex.
Liposomes demonstrate potential as delivery systems to combat drug-resistance
in cancer due to their versatility in loading. Liposomes possess the ability to load
multiple therapeutics to re-sensitize resistant cancer cells while simultaneously treating
those cells with a chemotherapeutic agent. Here, a liposomal carrier for both paclitaxel
and siRNA was designed and synthesized to provide a combinatorial therapy to resensitize drug-resistant ovarian cancer cells to paclitaxel and thereby increase the
efficacy of paclitaxel. A custom siRNA array was developed, and we identified three
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possible gene targets, ABCB1, JAK2, and CFLAR, involved in the development of drug
resistance in paclitaxel-resistant OVCAR3-TR ovarian cancer cells.
Two combinatorial, cationic liposome delivery systems were designed and
synthesized via the lipid film hydration method. Liposomes were characterized for size,
surface charge, stability, and loading efficiencies. We demonstrated efficient loading of
paclitaxel and protection of bound siRNA in both liposome formulations. Cellular uptake
of the liposomes was confirmed using fluorescence microscopy. Overall, the liposomes
show promise in loading both paclitaxel and siRNA to target genes involved in drugresistance development in ovarian cancer cells.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND

Ovarian cancer is the fifth leading cause of cancer death amongst women and
the most lethal gynecological cancer [1]. Over 22,200 new diagnoses and 14,000 deaths
are expected in 2018 [1]. The high death rate of ovarian cancer stems from late
diagnosis and lack of early symptoms of the disease. Around 60% of ovarian cancer
diagnoses occur in the distant or advanced stages of the diseases, resulting in a five-year
survival rate of only 21-29% [1]. However, in localized stages, the five-year survival rate
is 87-93% [1]. Without diagnostic advancements, there is a significant need to improve
upon current treatments to accurately target cancer cells and increase the efficacy of
delivered therapeutic agents.
Current diagnostics for ovarian cancer utilize cancer antigen 125 (CA-125) serum
levels, transvaginal ultrasonography, or imaging methods including computed
tomography (CT) or magnetic resonance imaging (MRI) in order to identify potentially
cancerous tissue. CA-125 is the most used diagnostic for ovarian cancer because serum
levels of CA-125 are typically elevated in more advanced stages of the disease [2].
However, measuring CA-125 levels alone is often not sufficient in diagnosing ovarian
cancer without the aid of other methods [2]. The most problematic characteristics of
CA-125 diagnostics include low sensitivity in stage 1 disease and low specificity due to
increased CA-125 levels in other cancers and benign conditions, like menstruation,
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pregnancy, endometriosis, and pelvic inflammatory disease [3]. Imaging methods,
including CT and MRI, have proven to be more reliable than CA-125 in diagnosis of the
first recurrence of ovarian cancer when overall survival and progression-free survival
were compared [4]. Currently, transvaginal ultrasonography is utilized when a patient
has suspected masses on their pelvis to identify the origin [5].
Upon diagnosis, the current standard of care for ovarian cancer treatment is a
combination of cytoreductive surgery and chemotherapy [6]. The order in which these
treatments occur depends on each patient and is ultimately decided upon by the doctor.
Combination carboplatin and paclitaxel remains the standard frontline chemotherapy
treatment for advanced ovarian cancer [7]. The time between initial resection and
initiation of chemotherapy regimens is a vital factor in predicting the overall survival of
women with advanced ovarian cancer, with an increased risk of death when the time
period surpasses 25 days [8]. However, despite first-line treatment, around 70% of
patients relapse [2]. Recurrent cancer is rarely treated with second-line surgery and the
focus shifts to chemotherapy instead because more problems arise when treating a
relapse. Alterations in the sensitivity of cancer cells to chemotherapeutics may occur
based on prior exposure to each type of therapeutic agent; thus, drug resistance may
become a challenge in treating recurrent cancer.

1.1 Drug Resistance Development in Ovarian Cancer
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The aggressive nature of advanced ovarian cancer is thought to be correlated to
the development of resistance to chemotherapeutics to which the patients are exposed.
High recurrence rates are problematic, but they provide an even greater challenge when
sensitivity to chemotherapy used in primary treatment decreases during secondary
treatment. Various factors and pathways influence the sensitivity of cells to drugs;
therefore, resistance cannot be reversed by only targeting one specific area or pathway.
In ovarian cancer, the main mechanisms of resistance include membrane transporter
activity [9], dysregulation of apoptosis [10], autophagy [11], cancer stem cells [12],
epigenetics [13], and the epithelial-mesenchymal transition [14]. However, other
unknown underlying factors could also be mediating the development of resistant
phenotypes.

1.1.1 Membrane Transporter Activity
Membrane transporters are involved in maintaining an equilibrium influx and
efflux of molecules in the cell, where a change in this equilibrium can change the
phenotype of the cell [15]. Chemoresistant phenotypes arise when a decrease in influx
of molecules is coupled with an increased efflux due to increasingly active membrane
transporters, reducing the cellular uptake, intracellular accumulation, and anticancer
activity of chemotherapeutics. The most studied and well-known culprits of
chemoresistance are ATP-binding cassette (ABC) membrane transporters, which
eliminate large molecules in order to protect the cell (Fig. 1.1).
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The ABC protein superfamily includes 49 proteins involved in drug resistance
from seven subfamilies [16]. Multidrug resistance (MDR) has been linked to
upregulation in ABCB1, ABCC1, and ABCG2, as well as many others [17,18]. ABCB1, also
known as multidrug resistance protein 1 (MDR1), codes P-glycoprotein (P-gp), a multidrug membrane transporter [19]. Normal function of P-gp includes the regulation of
apoptosis, which can be modified through transporting molecules into or out of the cell
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[19]. Overexpression of P-gp led to increased cell protection and decreased stem cell
differentiation, thereby, promoting cancerous activity [19].
Expression levels of MDR-related genes in ovarian cancer cells resistant to
chemotherapy drugs provide a possible parameter to use to analyze cross-resistance
between cell lines. High P-gp expression levels indicate drug resistance in W1 ovarian
cancer cell lines resistant to doxorubicin, paclitaxel, and vincristine. BCRP, or ABCG2,
expression indicates resistance in topotecan-resistant W1 cells [17]. Cross-resistance
discovered between the paclitaxel- and doxorubicin-resistant cell lines could be
problematic if doxorubicin is given as a second line treatment for paclitaxel-resistant
ovarian cancer. The work of Januchowski and colleagues expands upon earlier studies
demonstrating that P-gp, MDR1, MDR2, and LRP drug resistance-associated markers are
prognostic factors in ovarian cancer diagnoses [20].

1.1.2 Dysregulation of Apoptosis
Dysregulation of apoptosis pathways in the cell can increase cell survival and
avoidance of drug-induced death. Numerous signaling pathways are involved in
controlling apoptosis pathways in a cell, including PI3K/Akt and NF-kB. The Bcl-2 family
of regulatory proteins mediates cell death by either inhibiting or inducing apoptosis
through a balance between pro- and anti-apoptotic proteins. Bcl-2 activates the Akt
pathway activity [21], and the NF-kB signaling pathway has been found to be activated
by Akt through the presence of mTOR [22]. The upregulation of Bcl-2 anti-apoptotic
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proteins is characteristic of cancer and increased proliferation and survival of cancer
cells. In paclitaxel-resistant SKOV3 cells, downregulation of Bcl-2 and hTERT increased
apoptosis after 6 days of combination treatment with epigallocatechin gallate and
sulforaphane [23].
The upregulation of signaling pathways, like PI3K/Akt and NF-kB, has also been
found to play an important role in developing resistance to chemotherapy. The
development of resistance to cisplatin, paclitaxel, and bevacizumab in ovarian cancer
cell lines has been linked to activation of the Akt pathway. In A2780 cisplatin-resistant
and CAOV3 cells, blockage of the Akt pathway via gemcitabine treatment inhibited
cisplatin-induced Akt activation, and co-treatment with cisplatin completely inhibited
the invasion of both cell lines in matrigel [24]. Also, overexpression of Akt in cisplatinresistant A2780 cells led to an increase in cells escaping the natural killer cells of the
immune system and an increase in the expression of anti-apoptotic proteins, CIAP-1 and
-2 [25].
In paclitaxel-resistant A2780, SKOV3, and MPSC1 cells, the downregulation of the
Akt and NF-kB pathways through tectorigenin treatment resulted in sensitization of cells
to paclitaxel and enhanced growth inhibition, compared to paclitaxel treatment alone
[26]. Tectorigenin also inhibited the nuclear translocation of NF-kB and the expression
of many NF-kB-dependent genes known to be involved in drug resistance, including FLIP,
XIAP, Bcl-2, and Bcl-xL [26]. Akt pathway activation in endothelial ovarian cancer cells,
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OVCAR-3 and SKOV3 cell lines, demonstrated characteristics of a niche for residual
cancerous tissue with resistance to bevacizumab [27].

1.1.3 Autophagy
In addition, autophagy plays a role in the sensitivity of cancer cells to
chemotherapy. Autophagy is used by cells to aid in survival under nutrient starvation or
other cellular stresses through digestion of their own cellular components to maintain
energy. Cells can use autophagy as a protective mechanism against stresses, like the
damaging effects of chemotherapy, resulting in decreased anticancer response [28].
Cisplatin-resistant ovarian cancer cells, OV433-CR, demonstrated increased activation of
the ERK pathway, which promotes autophagy induction. Inhibition of ERK/MAPK activity
decreased autophagy and increased sensitivity of cells to cisplatin-induced death [29].
The inhibition of autophagy in cisplatin-resistant SKOV3 and A2780 cells also increased
apoptosis via the overexpression of miR-152, an autophagy-regulating miRNA involved
in cisplatin resistance [30].
Reactive oxygen species (ROS) maintenance is vital in all cells in order to respond
to environmental changes. When ROS production increases past an allowable threshold,
the expected outcome is cell death. However, there is a suspected relationship between
autophagy and ROS production. Autophagy is believed to be a protective mechanism
when dealing with stress and ROS generation in ovarian cancer cells, increasing as ROS
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increases [31]. This extended protection may provide cancer cells a longer time to repair
DNA damage from chemotherapy, thus decreasing the efficacy of chemotherapeutics.

1.1.4 Cancer Stem Cells
Autophagy also plays a role in mediating chemoresistance of cancer stem cells
(CSCs) [11]. A recent discovery proved that cancer stem cells are involved in the
development of drug resistance due to their stem cell-like phenotype (Fig. 1.2).
Particularly, their ability to resist apoptosis by DNA damage prolongs the survival of
cancer stem cells in cancer tissue [10]. Cancer stem cell phenotypes include
characteristic evasion of apoptosis in hypoxic conditions, increased growth potential
[32], and increased CSC marker aldehyde dehydrogenase isoform 1 activity [33]. CSCs
from the HO8910 cell line demonstrated faster growth and enhanced survival potential
in a 3D cell culture as well as increased tumorigenicity in a xenograft mouse model
compared to the parental HO8910 cells. Also, CSCs showed increased resistance to 5fluorouracil, cisplatin, and carboplatin as well as high expression of MDR genes, ABCB1,
ABCG2, MMP2, and MMP9 [32]. Recent efforts have explored the mediation of drug
resistance via cancer stem cell elimination. In SKOV3-spheroid cells, knockdown of KLF5
is a promising target to eliminate CSCs, shown by a decrease in survivin expression and
increase in sensitivity to paclitaxel and cisplatin [34].
Aldehyde dehydrogenase isoform 1 (ALDH1) is an emerging marker, which when
used in combination with other stem cell markers, can identify populations of cancer
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stem cell populations in ovarian cancer. ALDH1 activity, measured by fluorescentlylabeled ALDH1, showed ALDH1-bright cells were more common in ES-2 and CP70
ovarian cancer cell lines and showed increased chemoresistance compared to SKOV3,
OVCAR3, and A2780 ovarian cancer cells that did not express high levels of ALDH1 [35].
Tumor samples from 84 subjects indicated the association of cancer stem cell marker
ALDH1 with chemoresistance and poor clinical outcomes in epithelial ovarian cancer
patients [35].
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1.1.5 Epigenetics
Epigenetics and other changes in the tumor microenvironment, including DNA
methylation, histone modification, and microRNA expression, have become greater
focuses in the drug resistance mechanisms of ovarian cancer over the last decade [13].
Current studies are exploring various miRNAs and DNA modifications in order to exploit
specific pathways involved in the development of chemoresistance in ovarian cancer
[36,37]. DNA methylation involves the addition of a methyl group to DNA without
changing the sequence, but when methylation occurs in the promoter region of a gene,
the gene can be repressed. Hypermethylation of genes is common in drug-resistant
ovarian cancer cells, including A2780 cells resistant to cisplatin. In a study of the
methylome and gene expression in wild-type and resistant A2780 cells, 13 out of 41
genes were consistently upregulated in the A2780/CP70 cisplatin-resistant ovarian
cancer cells compared to parental A2780 ovarian cancer cells, where initially
methylated-MLH1, a DNA repair gene, played a role in re-sensitizing cells to cisplatin
when demethylated in vitro [38]. DNA methylation has been found to interfere with
cisplatin-sensitivity in both A2780 and OVCAR3 cells through overexpression of MAFG, a
DNA binding transcription factor. MAFG expression can be directly regulated by miR-7,
creating a potential target for mediating drug resistance with MAFG and a factor for
prognosis in the methylation status of miR-7 [39].
Furthermore, epigenetic silencing, or the process of non-mutational change in
gene expression that can be passed down from generation to generation in cells [40],
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continues to reveal prognostic biomarkers and potential therapeutic targets in drugresistant ovarian cancer cells. Epigenetic silencing of miR-199b-5p in cisplatin-resistant
A2780 and C13* cells demonstrated activation of the JAG1-mediated Notch1 signaling
pathway, encouraging the development of chemoresistance. Downregulation of miR199b-5p is associated with poor clinical outcomes in ovarian cancer patients; thus,
microRNA levels could be a prognostic factor and JAG1 a therapeutic target in cisplatinresistant ovarian cancer [41].
Similarly, silencing of miR-130b, in cisplatin-resistant A2780 and paclitaxelresistant A2780 and SKOV3 cells, promote drug resistance through colony stimulating
factor 1 (CSF1) targeting. MiR-130b silencing was inversely related to DNA methylation
and resistance development. Thus, CSF1 knockdown is a potential treatment to resensitize cells to chemotherapy and improve clinical outcomes [36]. Epigenetic silencing
of BLU, a tumor suppressor gene, in paclitaxel-resistant ovarian tumor samples led to
resistance development, and BLU methylation indicated a shorter progression-free and
overall survival in patients. BLU methylation levels may be a promising prognostic
biomarker in advanced serous ovarian carcinoma patients [42].

1.1.6 Epithelial-Mesenchymal Transition
Paclitaxel-resistance in A2780 cells induces morphological changes consistent
with epithelial-mesenchymal transition (EMT) and an increase in EMT-related
biomarkers confirmed by RT-PCR. Activation of the PI3K/Akt pathway is vital to EMT;
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thus, when PI3K was inhibited, paclitaxel sensitivity increased and cytoskeleton
morphology shifted toward an epithelial phenotype [43]. In A2780 cells resistant to
cisplatin, Snail and Slug, EMT transcription factors, contribute to resistance as evidenced
by cell morphology changes, from spherical epithelial cells to spindle-like cells with
formation of pseudopodia. A whole transcriptome microarray revealed overexpression
of E-cadherin transcriptional repressors, Slug, Snail, TWIST2, and ZEB2, and
downregulation of E-cadherin in A2780-cis cells compared to the parental A2780 line.
Knockdown of Snail and Slug reversed the EMT phenotype and reduced resistance to
cisplatin [44]. Snail, Slug, and TWIST upregulation were also linked to platinum
resistance and EMT phenotypes in stage III-IV epithelial ovarian tumor biopsies.
Activation of the TGF-β pathway led to activation of EMT, and relapse in 70% of patients
was associated with increased activation of the TGF-βR2 pathway [45].
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CHAPTER TWO
TARGETED DELIVERY SYSTEMS TO COMBAT DRUG RESISTANCE IN OVARIAN CANCER

2.1 Delivery Strategies for Overcoming Drug Resistance
In order to combat different mechanisms of drug resistance development, a
variety of therapeutics and delivery strategies have been studied to target and reverse
chemoresistance in cancer cells. Currently, in ovarian cancer, the most common
methods of reversal are treatment with siRNAs to manipulate the dysregulated genes
and inhibitors to target the imbalance of efflux and influx in cells. Anti-resistance
therapeutics aim to re-sensitize the cancer cells to chemotherapy drugs so further
treatment can be administered to increase progression-free survival of cancer patients.
In order to deliver siRNAs, inhibitors, and chemotherapeutic agents, alone or in
combination to chemo-resistant cancer cells, many targeted delivery systems have been
developed. Current methods include a variety of nanocarriers to increase the efficacy of
chemotherapy drugs and other therapeutic agents while also decreasing negative side
effects, like systemic toxicity. The nanocarriers are developed from polymers, lipids,
peptides, and other inorganic molecules, as depicted in Figure 2.1.
The delivery systems used for combatting treatment in drug-resistant ovarian
cancer are classified into two groups, single agent delivery or combination delivery.
Single-agent delivery systems are used to increase the targeting and efficacy of one
therapeutic agent. Typically, a drug carrier is used to increase cellular uptake by cancer
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cells compared to free drug treatment and decrease off-target effects, limiting the
damage to healthy cells. The goal of combination treatment is to maximize the
synergistic ability of two compounds to increase anticancer effects while also decreasing
adverse side effects of the free therapeutics.
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Nanoparticles for single-agent use have already performed well in clinical trials.
One of the most common, liposomal doxorubicin, is an FDA-approved chemotherapy
drug and is widely used in cancer treatment. The benefit of the liposomal form of the
drug is increased circulation time compared to free doxorubicin due to protection
against destruction by the immune system [46]. Similar to this idea, many current
studies seek to improve the efficacy of common chemotherapeutic agents through
development of targeted therapies.

2.1.1 Lipid
Lipid-based delivery systems are advantageous due to their drug loading
versatility, utility for combination therapies, ability to modify surface characteristics, and
decreased toxicity compared to free therapeutics. Drug loading in lipids, especially
liposomes, is optimal because hydrophilic and hydrophobic drugs can both be loaded.
The hydrophobic tails of lipids are sufficient environments for hydrophobic drugs to
reside, while hydrophilic drugs can be loaded into the center of liposomes. In order to
combat drug resistance in ovarian cancer cells, the versatility of lipid delivery systems
can elicit greater anticancer effects through targeting activity of efflux transporters,
cancer stem cells (CSCs), metabolism dysregulation, and hypoxic environments.
Increasing intracellular accumulation of therapeutics remains one of the main
goals of nanoparticle delivery systems, thereby decreasing off-target toxicity and
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increasing the efficacy of the delivered therapeutics. In drug-resistant ovarian cancer,
increasing uptake of therapeutics is necessary to increase the concentration of drugs
ultimately reaching the targeted tumor site. Solid lipid nanoparticles loaded with
paclitaxel and doxorubicin have exhibited increased cellular uptake into A2780res and
SKOV3TR drug-resistant ovarian cancer cells, increasing the anticancer effects of the
treatment compared to free drug treatment alone [47,48].
Increase in intracellular uptake has also been demonstrated through the use of
surface-modified liposomes for targeting ovarian cancer cells. Folic acid is used to target
folate receptors, which are overexpressed on the surface of ovarian cancer cells. One
study showed paclitaxel-loaded nanoparticles decorated with folic acid demonstrated
increased cellular uptake and inhibited growth and doubling time in SKOV/TAX cells
compared to undecorated paclitaxel nanoparticles [49]. The addition of polyethylene
glycol (PEG) to lipid nanoparticles also increases the stealth and uptake of the particles
into drug-resistant SKOV3 ovarian cancer cells by evading efflux transporters [50].
Due to a relationship between CSC activity and aggressiveness of tumors,
decreasing activity of CSCs has gained increasing popularity as a method to target drug
resistance development in ovarian cancer cells. A novel, liposomal form of paclitaxel has
been found to suppress CSC sub-populations, from drug-resistant ES-2 ovarian cancer
cells, when delivered intraperitoneally compared to intravenously administering
paclitaxel alone, as indicated by decreased levels of CSC-markers, CD44, CD24, and
CD133 [51]. Metabolic reprogramming from glycolysis to oxidative phosphorylation was
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also induced through reactivation of p53 in resistant ES-2 cells resulting in better control
of tumor growth [51].
The ability to deliver treatments in combination provides a promising method to
synergistically enhance the efficacy of therapeutics, especially those used to treat drugresistance in ovarian cancer. Crosslinked multilamellar liposomes developed to deliver
carboplatin and paclitaxel, two of the most common intravenous chemotherapeutics,
were shown to increase anticancer effects in NCI/ADR-RES ovarian cancer cells in vitro
and in OVCAR8 ovarian cancer xenograft mice models [52]. Also, in vitro studies showed
decreased cancer stem cell activity in NCI/ADR-RES cells, where ALDH+ cells decreased
from 57.3% in the untreated control to 30.2% in the resistant cells treated with the
combination liposomes [52].
Combination therapies have also been used to mediate resistance by avoiding
efflux of chemotherapeutics by p-gp membrane transporters and hypoxia-induced
resistance on ovarian cancer cells. Liposomes containing paclitaxel and tariquidar, a
third-generation p-gp inhibitor, blocked proliferation and induced G2-M phase arrest in
SKOV3-TR and HeyA8-MDR drug-resistant ovarian cancer cells in vitro. The combination
liposomes reduced tumor weight to 16.9% from 43.2%, in mice xenografts with
orthotopic HeyA8-MDR tumors compared to paclitaxel-only liposomes [53]. To address
resistance related to hypoxia, liposomes containing doxorubicin and antisense
oligonucleotides (ASO) targeting HIF-1α mRNA were delivered to A2780/AD
doxorubicin-resistant ovarian cancer cells in vitro and athymic nu/nu mice with
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A2780/AD subcutaneous tumors in vivo [54]. Confocal microscopy and in vivo
fluorescence imaging identified intracellular localization of the combinatorial liposomes,
and RT-PCR and IHC-staining showed decreased expression of HIF-1α when compared to
free or liposomal doxorubicin without ASOs. Increased cell death signals were shown
through expression of apoptotic proteins, BAX, CASP3, CASP9, and P53, as well as
decreased expression of VEGF, identifying a decrease in tumor vascularization [54].
The various modifications of liposomal delivery of therapeutics in order to
increase targeting, intracellular uptake, and efficacy of drug-resistant cancer treatments
are promising in that the delivery systems can be modified to exploit the different
mechanisms of resistance and overexpression of receptors in cancers on an individual
basis. Personalized cancer treatment could lead to higher remission rates and lower
incidence of drug resistance in secondary treatment. Liposomal therapeutic options
show promise in future applications of targeted therapies as few treatments have
reached clinical trials.

2.1.2 Polymer
Polymer nanoparticles are the most common synthetic delivery systems utilized
in targeted treatments for drug-resistant ovarian cancer. Similar to lipids, polymers
possess the ability to increase intracellular accumulation of therapeutics, increase
efficacy of treatments via surface-conjugated targeting moieties, deliver synergistic
combination agents, and sustain the release of therapeutics. Increased accumulation
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and efficacy of paclitaxel and cisplatin in drug-resistant A2780 ovarian cancer cells
resulted from single-agent delivery in poly (n-butylcyanoacrylate) nanoparticles
compared to free paclitaxel or cisplatin treatment [55,56].
Similar to surface modifications in lipids, the addition of targeting moieties in
polymer-based nanoparticles has been shown to increase uptake of therapeutics
thereby increasing anticancer effects. Folate-targeted triblock copolymer nanoparticles
delivered TLR4 siRNA and paclitaxel to drug-resistant SKOV3 ovarian cancer cells in vitro,
to re-sensitize cells to paclitaxel and mediate TLR4-driven resistance [57]. Folate has also
been used to increase uptake of paclitaxel-loaded PLGA nanoparticles [58]. In addition
to folate, biotin is a common targeting ligand used for ovarian cancer due to its affinity
for EGF receptors, which mediate resistance via the epithelial-mesenchymal transition.
Biotinylated-PAMAM dendrimers exhibited a ten-fold increase in intracellular
accumulation of cisplatin in A2780-CP70 cisplatin-resistant ovarian cancer cells
compared to free cisplatin treatment alone [59]. Hyaluronic acid is an important
targeting moiety for ovarian cancer cells as it targets CD44, a cancer stem cell and drug
resistance marker. HA-targeted PEI/PEG nanoparticles were developed to deliver MDR1
siRNA and paclitaxel to OVCAR8TR cells in vitro [60]. MDR1 siRNA knockdown increased
sensitivity of cells to paclitaxel by decreasing p-gp activity and increased cellular uptake
by targeting CD44, compared to untargeted nanoparticles [60].
Combinatorial delivery of anticancer therapeutics is an advantage of the
versatility of polymer-based nanoparticle design. Like lipids, paclitaxel and p-gp inhibitor

19

molecules, tacrolimus and borneol, have been delivered in combination to elicit a
greater anticancer effect than either of the drugs alone, by decreasing efflux and
increasing intracellular accumulation of paclitaxel in A2780 paclitaxel-resistant ovarian
cancer cells in vitro [61,62]. The combination of two molecular therapeutics was also
demonstrated by co-encapsulation of doxorubicin and rhein in vitamin E-PEG
nanomicelles and of paclitaxel and lonidamine in PCL-EGFR targeted NPs. In comparison
to free drug treatment, both types of polymer nanoparticles exhibited increased tumor
targeting and cytotoxic activity when studied in vitro on drug-resistant SKOV3 ovarian
cancer cells [63,64]. Combinatorial delivery also includes simultaneous delivery of
multiple siRNA, as demonstrated by the delivery of MDR1 and PKM2 siRNA in HAtargeted PEI-PEG NPs to SKOV3TR ovarian cancer cells. The synergistic ability of the dual
silencing of multidrug resistance protein and pyruvate kinase isoform 2 showed a 1.3
fold decrease in IC50 value of paclitaxel when drug delivery followed siRNA delivery in
SKOV3TR cells, but there was no significant difference in IC50 when delivered to wildtype SKOV3 cells [65].
The most advantageous quality of polymer-based sustained release of
therapeutics due to stimuli-responsive or biodegradable characteristics. Sustained
release allows the drug to be exposed to the cancer cells for a longer period of time,
which leads to increased efficacy of the therapy. pH-responsive polymer nanoparticles
exploit the acidic environment of tumors in order to maintain a sustained release of
therapeutics. Poloxamer 407 vitamin E-TPGS mixed micelles functionalized with folate
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exhibited decreased efflux of doxorubicin in doxorubicin-resistant SKOV3 ovarian cancer
cells, where accumulation increased 24% with the addition of poloxamer 407 and 264%
with the addition of TPGS, when compared to efflux rates of untreated Dox-resistant
SKOV3 cells [66]. The increased accumulation of doxorubicin led to an increase in
doxorubicin binding to DNA, increasing cytotoxicity compared to free doxorubicin.
Biodegradable polymers, like polylactic acid (PLA), polyglycolic acid (PGA), or a
combination of the two, PLGA, promote sustained release of therapeutics through
degradation of the delivery systems. PLGA nanoparticles developed with a polydopamine and PEG coating prevented rapid release and clearance of paclitaxel in a
BR5FVB1-Akt murine ovarian cancer model [67]. Mice treated with the PLGA NPs
showed an 8-fold increase in paclitaxel concentration in the peritoneal cavity than mice
treated with free paclitaxel, while the systemic circulation of paclitaxel was three times
higher in the free paclitaxel treatment than the nanoparticle treatment [67]. PLGA
nanoparticles were shown to sustain release of diphtheria toxin-subunit A suicide genes
in chemo-resistant ovarian tumor-bearing SCID mice, inhibiting tumor growth [68].
Chitosan-coated PLA NPs mediated release of p62 siRNA, β5 plasmid, and cisplatin, in
C13 cisplatin-resistant ovarian cancer cells in vitro, as demonstrated by a 26% decrease
in IC50 of cisplatin, compared to only 15.2% with delivery of sP62 alone or 8% with pβ5
[69].
Overall, polymer nanoparticles possess many desirable qualities for targeted
therapy options in the reversal and treatment of drug-resistant ovarian cancer. While
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qualities like sustained release and specific stimuli response favor polymer systems over
lipids, most of the concepts of the two types of delivery systems remain similar. Thus,
the addition of targeting ligands, the potential to co-encapsulate therapeutics, and the
increase in intracellular accumulation and cytotoxicity are all important to developing a
successful targeted therapy for treatment of drug resistance in ovarian cancer.

2.1.3 Inorganic
Beyond lipids and polymers, other nanoparticles have become popular in
studying reversal of drug resistance in ovarian cancer, specifically, silica and metal
nanoparticles. Mesoporous silica nanoparticles (MSNs) are desirable for the delivery of
siRNA specifically to perinuclear targets in vitro and in vivo. MSNs have been utilized to
deliver and knockdown TWIST siRNA to decrease tumor burden in mice and target the
epithelial-mesenchymal transition when treated concurrently with cisplatin compared
to cisplatin alone [70]. Combination therapy has been attempted with MSNs as well,
delivering doxorubicin and Bcl-2 siRNA to control and decrease apoptosis-related
resistance. The off-target release of doxorubicin was minimal and the intracellular
localization of the agents increased indicating successful management of resistance and
increased efficacy of doxorubicin [71].
Metal nanoparticles, such as iron oxide, silver, and copper, are modified with
organic materials and loaded with therapeutic agents to treat drug-resistant ovarian
cancer. Iron-oxide nanoparticles as delivery systems for doxorubicin have been shown
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to sustain slow release of DOX at slightly acidic pHs and avoid drug efflux pumps [72]. In
addition, release of doxorubicin from mesoporous iron-oxide nanoparticles has also
been studied for combination therapy with hyperthermia, where DOX burst release
occurs upon magnetic heating [73]. Lycopene-reduced graphene oxide-silver
nanoparticles were developed for co-delivery with trichostatin A. The combined effects
of these two agents decreased cell viability in a dose-dependent manner through an
increase in apoptosis due to DNA fragmentation and double strand dysfunction [74].
Similarly, phosphorous dendrimers were modified with copper to target BAX pathways.
The copper-phosphorus structures increased apoptosis by increasing activation of the
BAX signaling pathway [75]. The benefit of using a metal nanoparticle is that therapeutic
agents may not be needed as some metals elicit anticancer effects alone.

2.1.4 Theranostic
Lastly, some delivery systems aim to improve treatment and diagnostic abilities
in a single therapy by personalization of therapy to meet patient’s varying needs. These
methods are designated as theranostic approaches in which nanoemulsions of
chemotherapeutic drugs are delivered and imaged to predict the success of the therapy
in different patients [76]. Nanoemulsions load platinum drugs and doxorubicin, and they
are functionalized with folate in order to increase on-target localization of the particles.
Targeted nanoemulsions have demonstrated increased cytotoxicity due to efficient
cellular uptake than treatment with free chemotherapeutic drugs [77,78].
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2.2 Current Clinical Trials
Overall, the versatility of nanoparticle delivery systems in the reversal and
treatment of drug-resistant ovarian cancer seems to be a promising quality; however,
targeted therapy research is cutting-edge and there has yet to be much translation from
the research setting into the clinical setting. Clinical trials for ovarian cancer currently
focus on options improving traditional chemotherapy drugs to treat recurrent or
resistant cancer through modifications in dosing regimens, differing combinations of
drugs, and changing the method of delivery of the drugs, as laid out in Table 2.1. The
more recent targeted therapies have yet to become popular in clinical trials due to poor
translation of treatments, but a few have been tested as second, third, or last lines of
therapy.
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Table 2.1.Clinical Trials for Ovarian Cancer Treatment. Recent clinical trials for ovarian cancer characteristics and
phases, with accompanying results.
Drug(s) In trial

Phase Delivery Method/Regimen

Drug mechanism(s)

Paclitaxel

I

Novel liposomal platform[79]

Pertuzumab
with topotecan
or paclitaxel

I

IV pertuzumab every 3 weeks
with either topotecan every 3
weeks or paclitaxel weekly[80]

Paclitaxel and
carboplatin

II

Temsirolimus

II

Cremophor-free polymeric
micelles of paclitaxel IV with
carboplatin every 3 weeks[81]
Weekly IV infusions[82]

Paclitaxel stabilizes microtubules during mitosis and
leads to mitotic arrest
Pertuzumab inhibits ligand-dependent HER2-HER3
dimerization and reduces signaling through PI3K
pathway; Topotecan inhibits topoisomerases to cause
double strand DNA breakage and cell death
Carboplatin inhibits DNA synthesis by causing intraand inter-strand crosslinking in DNA

Olaparib

II

Oral capsules[83]

Pazopanib

II

Albumin-bound
paclitaxel

II

Paclitaxel

II

Sorafenib with
paclitaxel and
carboplatin

II

Daily pazopanib with or
without weekly paclitaxel[84]
Cremophor-free nanoparticle
of albumin-stabilized paclitaxel
IV[85]
Lipid core nanoparticles weekly
IV infusion[86]
Paclitaxel and carboplatin IV
infusions with or without twice
daily sorafenib orally[87]
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Temsirolimus inhibits mTOR leading to cell cycle
arrest in the G1 phase and inhibiting tumor
angiogenesis
Olaparib inhibits PARP enzymes and DNA repair
Pazopanib inhibits tyrosine kinase for antiangiogenic
activity
Paclitaxel stabilizes microtubules during mitosis and
leads to mitotic arrest
Paclitaxel stabilizes microtubules during mitosis and
leads to mitotic arrest
Sorafenib inhibits tyrosine kinases in Raf/MEK/Erk
pathways and induces autophagy

2.3 Conclusion and Future Steps
Due to the aggressive malignancy, the limited early diagnostics, and the potential
of drug resistance in ovarian cancer, there is a significant need for increased efficacy and
specificity in treatment. Without much-needed advancements in diagnostic methods
and patient compliance for screenings, the only option to limit the negative effects of
ovarian cancer is to improve treatment success. Reversal of drug resistance is currently
at the forefront of ovarian cancer research, showing promising results in vitro and in
vivo. Numerous inhibitors and siRNA have been successful in re-sensitizing cells to
chemotherapy, including P-gp inhibitors, PARP inhibitors, and siRNA to modify
expression in signaling pathways important for cancer proliferation and progression. The
success of these inhibitors, while promising, remains low due to the complexity and
interdependence of mechanisms protecting the cells from chemotherapeutic agents.
Nanoparticles have become an increasingly popular option to deliver drug
resistance reversal agents in combination with chemotherapeutic agents to achieve
greater anti-cancer effects without increasing the danger of therapy to patients.
Nanoparticles can be developed from lipids, polymers, inorganic materials, or a
combination of the molecules in order to decrease toxicity of the drugs being delivered.
However, the significance of nanoparticle delivery systems actually lies in the ability to
modify particles to increase targeting specificity, increase intracellular accumulation,
and decrease premature clearance of the drugs before reaching the targeted area.
Translation from in vivo studies to clinical trials has been one of the largest obstacles in
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producing new treatment options for current ovarian cancer patients. Recently, a few
nanoparticle-based therapies have made their way into clinical trials, with hopes that as
more research is done on targeted therapies in ovarian cancer models, the number of
potential treatments reaching clinical trials will increase.
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CHAPTER THREE
RESEARCH AIMS

3.1 OBJECTIVES
Ovarian cancer is the deadliest gynecological malignancy and the fifth leading
cause of cancer-related death overall. Around 60% of ovarian cancer cases are
diagnosed in the distant stages, where the survival rate is only 21-29% [1]. The
aggressiveness of the disease lies in the high rates of recurrence and the development
of drug resistance after initial treatment. 70% of ovarian cancer patients will experience
a recurrence of their cancer [2], where the development of resistance to prior
chemotherapy regimens creates difficulty in determining an appropriate second-line
regimen. Currently, the standard treatment of a recurrence is to choose a
chemotherapy drug that has not shown cross-resistance with the first regimen.
However, some tumors will develop resistance to many chemotherapy drugs. Thus,
there is a significant need for therapies to increase the survival rate of drug-resistant
ovarian cancer.
The objective of this research is to identify potential gene targets involved in the
development of paclitaxel-resistance in ovarian cancer cells. Initial treatment of ovarian
cancer includes a regimen consisting of cycles of a platinum-based DNA-alkylating agent,
carboplatin or cisplatin, and paclitaxel, a microtubule stabilization agent [88]. Therefore,
the effectiveness of secondary treatments containing paclitaxel decreases if paclitaxel-
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resistance has developed. The overall goal of this research is to synthesize and
characterize cholesterol- and cholesteryl hemisuccinate (CHEMS)-based liposomal
combination delivery systems for siRNAs, specific to gene targets with identified
involvement in drug resistance in ovarian cancer cells, and paclitaxel to synergistically
increase the efficacy of paclitaxel in drug-resistant ovarian cancer.
Through completion of the following aims, I will collect the data necessary to
identify potential gene targets involved in the development of paclitaxel-resistance, as
well as synthesize and characterize two liposomal carriers with the ability to encapsulate
and deliver paclitaxel and siRNAs to drug-resistant ovarian cancer cells. Comparison of
the two liposomal delivery systems will determine the potential of substituting CHEMS
for cholesterol to incorporate a pH-sensitive compound without compromising the
loading and delivery ability of the liposomes.
Aim 1: Identify gene targets involved in the development of paclitaxel-resistance in
ovarian cancer cells with a siRNA array. We will design a custom array of siRNAs specific
to genes involved in apoptosis, the cell cycle, and drug resistance development in
cancer. Through siRNA transfection with the custom array followed by paclitaxel
treatment, we will identify the siRNAs responsible for the greatest anticancer effect in
paclitaxel-resistant ovarian cancer cells. We hypothesize that the siRNAs which
demonstrate the greatest anticancer effect in combination with paclitaxel when
compared to treatment with paclitaxel alone, will correlate to genes involved in the
development of resistance in ovarian cancer cells.
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Aim 2: Synthesize and characterize cholesterol- and cholesteryl hemisucciante-based
liposomal carriers, and compare their ability to encapsulate and deliver both
paclitaxel and siRNA to drug-resistant ovarian cancer cells. We will synthesize cationic,
cholesterol-based liposomes and cholesteryl hemisuccinate-based liposomes and
examine the size, surface charge, encapsulation efficiency, siRNA binding, stability, and
cellular uptake of the liposomes. We hypothesize that both types of liposomes will be
positively charged and uniform in size. We also hypothesize that the liposomes will be
stable when paclitaxel is loaded in the hydrophobic region of the lipid bilayer and
negatively-charged siRNA is bound to the cationic lipid components. We believe that
cellular uptake will be achieved through endocytosis of the cationic liposomes. We
believe that cholesteryl hemisuccinate can be substituted for cholesterol in the
synthesis of the liposomes without compromising the encapsulation ability or stability of
the liposomes.

3.2 Approach
Aim 1:
After determining the IC50 value of paclitaxel in OVCAR3 and OVCAR3-TR, wildtype and drug-resistant ovarian cancer cells, we will evaluate the viability of OVCAR3-TR
cells after transfection with the custom siRNA array and 15 nM paclitaxel treatment
using an MTS assay. Gene targets will be chosen based on the siRNAs demonstrating the
greatest anticancer effects compared to treatment with paclitaxel alone. These chosen
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siRNAs will be used as therapeutics bound to the liposomes to re-sensitize cells when
delivered in combination with paclitaxel.
Aim 2:
After identification of the gene targets, we will synthesize and characterize the
liposomes using dynamic light scattering to determine size and polydispersity index of
the particles, and micro-electrophoresis with phase analysis light scattering to find the
zeta potential. Then, we will examine the encapsulation efficiency of paclitaxel in the
liposomes when loaded with 2.5 µg/mL of paclitaxel. The amount of drug loaded will be
determined with high-performance liquid chromatography (HPLC).
After determining paclitaxel loading, we will evaluate the binding/loading of
siRNA to the liposomes to quantify the amount of siRNA available for knockdown upon
delivery into the drug-resistant cells. Liposomes loaded with fluorescent non-targeting
siRNAs allow the use of fluorescence spectrophotometry to determine the amount of
siRNA bound to liposomes. siRNA binding will be further studied with a gel shift assay to
ensure binding and protection of siRNAs and stability of loaded liposomes.
Cellular uptake will be visualized using immunofluorescence, fluorescent labeling
of early endosomes, nuclear counterstaining, and fluorescent siRNA and Nile Red loaded
liposomes. OVCAR3-TR cells treated with 100 µM of liposomes will be fixed at 2 hour
time points, and fluorescence microscopy will be used to evaluate the intracellular
localization of the liposomes.
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CHAPTER FOUR
IDENTIFYING GENE TARGETS IN THE DEVELOPMENT OF PACLITAXEL RESISTANCE IN
OVARIAN CANCER CELLS

Due to lack of early symptoms, a majority of ovarian cancer diagnoses occur in
the distant stages, leading to a low five-year survival rate of about 21-29% [1]. Low
survival rates are believed to be linked to recurrence of cancer and development of drug
resistance after initial treatment, which involves tumor resection surgery and a
chemotherapy regimen, usually including cisplatin or carboplatin, both platinum-based
DNA-alkylating drugs, and paclitaxel, a microtubule inhibitor [6,88]. Without advances in
current diagnostic methods, there is a significant need to find a therapy that is effective
on drug-resistant ovarian cancer.
The underlying intracellular mechanisms responsible for resistance are complex
and intertwined, making it difficult to treat the disease by targeting only one
mechanism. Thus, combination therapy has been heavily researched as a treatment
option for drug-resistant cancer. Combination therapies allow two or more therapeutics
to be delivered simultaneously, with the goal of synergistically increasing the efficacy of
either treatment alone [89,90]. Therapeutics in combination therapies include
chemotherapeutics, inhibitor molecules, and siRNAs. Controlling expression of genes
that are believed to be involved in the development of drug resistance with siRNAs
could be vital in treating recurrent cancer and re-sensitizing cancer cells to cisplatin,
carboplatin, and paclitaxel [91,92]. siRNAs delivered into the cell form an RNA-induced
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silencing complex with proteins and specifically bind to target mRNA, interrupting
translation and degrading the mRNA [93]. siRNAs can target the various pathways
involved in the development of drug-resistance in ovarian cancer by knocking down
overexpressed genes coding for p-gp membrane transporters, apoptosis, autophagy,
cancer stem cells, epigenetics, and the epithelial-mesenchymal transition. Combination
therapies can elicit increased anticancer effects by using siRNAs or inhibitors to resensitize cells to chemotherapy drugs and treat the cells simultanously with delivered
chemotherapeutics.
Here, a custom siRNA array of gene targets involved in apoptosis and the cell
cycle was designed in order to identify genes that may be involved in the development
of drug resistance in ovarian cancer cells. The anticancer effect of siRNA transfection
followed by paclitaxel treatment was studied in OVCAR3-TR cells. We found five siRNAs
had significantly greater anticancer effects compared to treatment with paclitaxel alone.

4.1 MATERIALS AND METHODS
4.1.1 Materials
The custom siRNA array was designed by including siRNAs from apoptosis and
cell cycle gene libraries, as well as siRNAs recently shown in literature to play a role in
development of drug resistance, and purchased from Dharmacon (Lafayette, CO).
Transfection supplies including 5x siRNA buffer, GAPDH siRNA, and Non-targeting #5
siRNA were also purchased from Dharmacon. Lipofectamine RNAiMAX and OPTIMEM
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media were both acquired from ThermoFisher Scientific (Waltham, MA) as well as cell
culture reagents, fetal bovine serum (FBS), penicillin/streptomycin, and trypsin. The
OVCAR3 cell line was obtained from ATCC (Manassas, VA) and the OVCAR3-TR cell line
was a generous donation from Dr. George Duran at Stanford University. McCoy’s 5A
modified media, phosphate-buffered saline (PBS), RNA grade water, and dimethyl
sulfoxide (DMSO) were purchased from Fisher Scientific (Pittsburgh, PA). Paclitaxel was
obtained from LC Laboratories (Woburn, MA). Thiazolyl Blue Tetrazolium Bromide
(TBTB) was purchased from Sigma-Aldrich (St. Louis, MO). Cell Titer One Aqueous
Solution Cell Proliferation Assay was acquired from Promega (Madison, WI).

4.1.2 Cell Culture
The human ovarian carcinoma cell lines OVCAR3 and OVCAR3-TR were cultured
in McCoy’s 5A Modified Medium with 10% FBS and 1% antibiotic (100 IiU/mL penicillin
and 100 µg/mL streptomycin). Both cell lines were cultured in an incubator at 37°C with
5% CO2.

4.1.3 IC50 Studies
The half maximal inhibitory concentration (IC50) value of paclitaxel in OVCAR3
and OVCAR3-TR ovarian cancer cell lines was determined to find the level of resistance
in OVCAR-TR cells. Both cell lines were seeded at 35,000 cells/well in two 24-well plates
and allowed to attach overnight. Paclitaxel dissolved in DMSO was added to the cells
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and allowed to incubate in media containing 10% FBS with a final paclitaxel
concentration ranging from 0-10 nM in the OVCAR3 cells and 0-100 nM in the OVCAR3TR cells for 24 hours. After 24 hours, the cells were washed with PBS three times to
ensure the removal of drug and media was replaced for another 48-hour incubation
period. After a total of 72 hours post-treatment, the cytotoxicity of paclitaxel was
examined using an MTT assay. The media was removed from the cells and Thiazolyl Blue
Tetrazolium Bromide was dissolved in PBS at a concentration of 2 mg/mL and added to
the cells for a final concentration of 1 mg/mL. The cells were then incubated with TBTB
for 4 hours at 37°C. After incubation, the TBTB was aspirated from the cells and
formazan crystals were solubilized with 500 μL of DMSO in each well. The absorbance of
each well was measured at a wavelength of 540 nm on a Biotek Synergy plate reader
(Winooski, VT). Cell viability was normalized to untreated cells and calculated with the
equation below:
Absorbance

Cell Viability (%)= (Absorbance 540

(sample)

540 (control)

) x 100.

The ratio of IC50 values in the resistant OVCAR3-TR cells compared to the wild-type
OVCAR3 cells was calculated to determine the level of resistance.

4.1.4 siRNA Array for Gene Target Identification
A custom siRNA array was developed by identifying genes involved in apoptosis
and the cell cycle, as well as genes recently found to be involved in drug resistance
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development, specifically in ovarian cancer. After the IC50 values were determined, an
optimal paclitaxel treatment concentration (15 nM) was found through MTT studies for
the siRNA array experiment. OVCAR3-TR cells were seeded at 7,000 cells per well in a
96-well plate and incubated overnight to allow for attachment. The cells were
transfected with 50 nM siRNA from the custom array and from controls and incubated
at 37° C for 24 hours. Five controls were used for the array, GAPDH siRNA, a positive
targeting control, Non-targeting #5 siRNA, a non-targeting control, lipofectamine only,
free paclitaxel only, and an untreated control. 24 hours post-transfection, the
transfection media was removed and the cells were treated with 15 nM paclitaxel and
incubated for another 24 hours.
At the 48-hour time point, an MTS cell proliferation assay was performed using
the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay. The cells were incubated
for 2 hours at 37°C with 20 μL of the Cell Titer reagent. After incubation, absorbance
was measured using a Biotek Synergy plate reader (Winooski, VT) at an absorbance of
490 nm. Absorbance values were used to calculate cell viability compared to untreated
OVCAR3-TR cells using the equation:
Absorbance

Cell Viability (%)= (Absorbance 490

(sample)

490 (control)

) x 100.

The anticancer effects were determined by comparing the viability associated with each
siRNA in the array to the viability of cells treated with free paclitaxel only.
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Statistical analysis was performed on the viability data from the array to
determine significant anticancer effects. Gene targets were chosen based on the highest
mean anticancer effects as demonstrated by the lowest viability values.

4.1.5 Statistical Analysis
Quantitative data were presented as mean ± SEM of three independent
experiments. Statistical analysis was performed using a Student's t-test or one-way
ANOVA, with *P < 0.05, **P < 0.01, and ***P < 0.001, and a value of P < 0.05 was
considered statistically significant.

4.2 RESULTS
4.2.1 IC50 Studies
Drug-resistance is identified by an increase in half maximal inhibitory
concentration of a drug on cells. The results comparing anticancer activity of paclitaxel
in OVCAR3 cells to resistant OVCAR3-TR ovarian cancer cells indicated an increase in
IC50 value of paclitaxel in OVCAR3-TR cells. In the OVCAR3 cell line, the IC50 value of
paclitaxel was 4.29 ± 0.12 nM. The resistant OVCAR3-TR cells showed a ten-fold increase
in paclitaxel IC50 value, 43.10 ± 2.41 nM, indicating a more resistant phenotype toward
paclitaxel than the OVCAR3 cells.
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4.2.2 Identification of Gene Targets
A custom siRNA array (Fig. 4.1) was used to identify gene targets that may be
involved in the development of drug resistance in ovarian cancer. From the anticancer
effects determined via viability data, seven siRNAs demonstrated higher anticancer
effects than paclitaxel treatment alone in OVCAR3-TR cells in vitro. Out of the seven
siRNAs identified, five siRNAs demonstrated significantly higher anticancer activity than
paclitaxel treatment alone, including, CASP8AP2, PAK2, ABCB1, JAK2, and CFLAR (Fig.
4.2A-B). The three siRNAs the results in the lowest viability in combination with
paclitaxel compared to treatment with paclitaxel alone were chosen as gene targets.
ABCB1, which codes for ATP-binding cassette transporters and manages efflux of
molecules out of cells, demonstrated the third lowest viability at 49%. JAK2, Janus
kinase 2, which plays a role in signaling cell growth, exhibited the second lowest viability
at 34%. The lowest viability overall, 29%, was due to silencing CFLAR, an apoptosis
regulator protein that inhibits caspase-8 cleavage, thereby inhibiting apoptosis.
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CHAPTER 5
SYNTHESIS AND CHARACTERIZATION OF COMBINATION LIPOSOMES FOR TREATMENT
OF DRUG-RESISTANT OVARIAN CANCER

Liposomes are multifunctional nanoparticles and allow for loading of hydrophilic
and hydrophobic chemotherapeutics, singularly or simultaneously, for delivery to
targeted cancer cells. Liposomal formulations of chemotherapy drugs decrease
hypersensitivity and off-target toxicity of chemotherapeutics delivered systemically. By
encapsulating paclitaxel, a poorly water-soluble drug, in lipids, the goal is to decrease
hypersensitivity and adverse effects due to polyoxyl-35 castor oil, used as a solubilizing
vehicle to mediate intravenous delivery of the hydrophobic drug [94]. Many liposomal
formulations of paclitaxel have been through clinical trials in recent years and are
beginning to gain clinical relevance as treatments for patients with ovarian cancer [95].
Liposomes are not only useful for eliminating the need for harsh solvents or
vehicles needed for delivery of poorly water-soluble drugs, but also for their therapeutic
loading versatility. Liposomes contain a region where phospholipid tails overlap and
create a hydrophobic shell within the membrane bilayer, allowing for hydrophobic
molecules to be loaded and protected inside the membrane. The core of liposomes,
lined by the hydrophilic heads of phospholipids, creates a suitable environment for
loading hydrophilic drugs. Thus, liposomes possess the ability to co-load both
hydrophobic and hydrophilic drugs, a characteristic that can be exploited for increasing
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the efficacy of chemotherapeutics, especially in difficult to treat cancers [52]. In addition
to co-loading drugs, liposomes also can load nucleic acid therapeutics, including plasmid
DNA, siRNA, and antisense oligonucleotides, through electrostatic interactions with
cationic lipids, to regulate expression of cancer-related genes [96].
The benefits of combination delivery of therapeutics can be further improved by
modifying liposomes with surface ligands, antibodies, and stealth components [50,97].
Modifications can assist in targeting and reversing drug-resistance mechanisms in
ovarian cancer. Inhibition of drug resistance mechanisms combined with chemotherapy
treatment have shown increased anticancer effects in drug-resistant ovarian cancer
models compared to chemotherapy alone [98].
To address drug resistance in ovarian cancer, we synthesized cationic,
cholesterol- and cholesteryl hemisuccinate-based liposomes in order to deliver
paclitaxel in combination with siRNA targeting genes involved in the development of
drug resistance. The liposomes were designed to bind negatively-charged siRNA to
cationic lipid components and load hydrophobic paclitaxel into the membrane bilayer.
Characterization based on size, polydispersity index, and zeta-potential confirmed the
formation of cationic liposomes. Efficient loading of paclitaxel and binding of siRNA into
the liposomes as well as stability of the loaded liposomes were all demonstrated.
Quantification of siRNA in CHEMS-LPs demonstrated lower concentrations than CHOLLPs in the fluorescence study, however similar siRNA binding was shown in the gel shift
assay. Further analysis is needed to determine the loading potential of the CHEMS-LPs.
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Cholesterol-based liposomes mediated cellular uptake of Nile Red and fluorescent nontargeting #5 siRNA and CHEMS-LPs mediated uptake of fluorescent non-targeting #5
siRNA into OVCAR3-TR drug-resistant ovarian cancer cells.

5.1 MATERIALS AND METHODS
5.1.1 Materials
All lipid components, DOTAP, DPPC, and DSPE-PEG(2000), a mini hand extruder,
and 0.2 µm polycarbonate membranes were purchased from Avanti Polar Lipids, Inc.
(Alabaster, AL). Cholesterol, cholesteryl hemisuccinate, Nile Red, and chloroform were
obtained from Sigma Aldrich (St. Louis, MO). Methanol, glucose, and acetonitrile were
purchased from VWR (Radnor, PA). Paclitaxel was acquired from LC Laboratories
(Woburn, MA). Fluorescent non-targeting #5 siRNA and non-targeting #5 siRNA were
obtained from Dharmacon (Lafayette, CO). Electrophoresis materials including agarose,
TAE buffer, ethidium bromide, Ambion PUC19 RNA Ladder, and agarose loading dye
were purchased from Fisher Scientific (Pittsburgh, PA). Paraformaldehyde and Triton X100 were also purchased from Fisher Scientific. NucBlue ReadyProbes stain and Alexa488 Anti-rabbit secondary antibody were acquired from ThermoFisher Scientific
(Waltham, MA). EEA1 rabbit monoclonal antibody was purchased from Cell Signaling
Technology (Danvers, MA).

5.1.2 Cell Culture
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The human ovarian carcinoma cell line OVCAR3-TR was cultured in McCoy’s 5A
Modified Medium with 10% fetal bovine serum (FBS), and 1% antibiotic
(100iU/mLpenicillin/100ug/mL streptomycin). The cell line was grown in an incubator at
37°C with 5% CO2.

5.1.3 Liposome Synthesis
Cationic liposomes were formed by dissolving lipids at a 25:40:30:4 molar ratio
(DOTAP:DPPC:Cholesterol (or CHEMS):DSPE-PEG2000) in a 3:1 (v/v) mixture of
chloroform and methanol as previously described [99]. The solvent was evaporated at
40° C for 20 minutes and then the lipid film was allowed to vacuum dry for 2 hours to
ensure complete removal of solvent. Fluorescent non-targeting #5 siRNA was added to
RNA grade water with 5% glucose (w/v) and used to rehydrate the lipid film. The
mixture was then sonicated in an ultrasonic bath for 20 minutes, followed by extrusion
through a 0.2 µm filter membrane in a mini-hand extruder. After extrusion, the
liposomes were diluted to the desired working concentrations and stored at 4°C. The
same process was used to form liposomes containing cholesteryl hemisuccinate in place
of cholesterol.

5.1.4 Characterization of Liposomes
Size and polydispersity index of the liposomes at a concentration of 5 mM was
determined using Dynamic Light Scattering, while surface charge was determined via
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micro-electrophoresis and phase analysis light scattering (M3-PALS) using a Zetasizer
Nano ZS (Malvern Instruments, Malvern, UK). The Zetasizer was maintained at a
temperature of 25°C while obtaining measurements. A refractive index of 1.45, an
absorbance value of 0.001, and an angle of 173° was used to collect the intensity of
scattered light due to the nanoparticles. Intensity-based size distribution plots were
generated based on twelve separate measurements.

5.1.5 Liposomal Loading Efficiency of Paclitaxel
To release encapsulated paclitaxel from liposomes, liposomes were disrupted in
methanol by centrifuging at 13,000 rpm for 20 minutes prior to HPLC analysis. Loading
of paclitaxel into the liposomes was determined using an HPLC system consisting of a
Waters Model 2707 Autosampler connected to a 1515 Isocratic HPLC Pump (Waters,
Inc., Milford, MA). Samples of 50 µL were injected into a Waters Symmetry C18 (4.6 x 75
mm, 3.5µm) column, with a gradient flow of water and acetonitrile beginning at 66:34
(v/v) at a flow rate of 0.6 mL/min. The UV detector was set to 227 nm. The loading
efficiency was determined by comparing encapsulated paclitaxel to the initial amount of
paclitaxel dissolved with the lipids using the equation:
Loading Efficiency (%) = (

Amount of drug detected
Amount of drug initially loaded

5.1.6 siRNA Binding and Stability in Liposomes
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) × 100

Agarose gel electrophoresis was performed to determine the binding and
protection of siRNAs in the liposomes. Intact and disrupted liposome samples were
loaded into a 2% agarose gel in TAE buffer and ran for 60 minutes at 100V. The gel was
stained with ethidium bromide and imaged with a UV illuminator.
Binding of siRNA to liposomes can be estimated by utilizing fluorescent siRNA
and measuring the intensity of fluorescence when bound to liposomes. Fluorescence
spectroscopy was performed in a Synergy Biotek plate reader (Winooski, VT) to examine
the binding of siRNAs to the liposomes. Serial fluorescent siRNA dilutions were used to
create a standard curve. Liposome solutions, including both 5 mM and 500 mM stocks,
were used as samples and their fluorescence intensities were fit to the standard curve
to determine the amount of siRNA bound. Liposome samples disrupted with 0.1% Triton
X-100 were also used to examine the siRNA fluorescence intensity without interference
from the stable liposomes. Binding efficiency was calculated as:
Binding Efficiency (%)= (

Amount of siRNA detected
) ×100
Amount of siRNA initially added

5.1.7 Cellular Uptake of Liposomes
Cellular uptake and intracellular accumulation of cholesterol-containing
liposomes loaded with fluorescent non-targeting #5 siRNA and Nile Red were visualized
using fluorescence microscopy. OVCAR3-TR cells were seeded at 35,000 cells per well in
24-well plates and incubated to allow attachment overnight. The cells were treated with
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liposomes at a final concentration of 50 µM and incubated for 4 or 8 hours. At 4 and 8
hours, the cells were stained with NucBlue ReadyProbes nuclear stain and imaged using
an EVOS FL Cell Imaging System (ThermoFisher Scientific, Waltham, MA).
Immunofluorescence assays were performed on OVCAR3-TR cells treated with
cholesterol- and CHEMS-containing liposomes loaded with fluorescent non-targeting #5
siRNA and paclitaxel. OVCAR3-TR cells were seeded at 35,000 cells per chamber on 8chamber collagen I-coated culture slides and incubated overnight for attachment. The
cells were then treated with 50 µM liposomes containing cholesterol or CHEMS and
incubated for 2 hours. OVCAR3-TR cells were fixed with 4% paraformaldehyde and
permeabilized with 0.1% Triton X-100 in PBS. The cells were incubated at 4°C overnight
with primary EEA1 antibody solution. Following incubation, cells were washed three
times using PBS and incubated with Alexa Fluor 488-conjugated secondary antibody
solution. Nuclear material was counterstained with mounting media containing DAPI.
Fluorescence microscopy was used to visualize cellular uptake and intracellular
accumulation of the liposomes.

5.1.8 Statistical Analysis
Quantitative data were presented as mean ± SEM of three or more independent
experiments. Statistical analysis was performed using a Student's t-test.

5.2 RESULTS
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5.2.1 Characterization of Liposomes
Two formulations of liposomes were synthesized using the same lipid film
hydration method to create liposomes containing cholesterol (CHOL-LPs) and liposomes
containing cholesteryl hemisuccinate (CHEMS-LPs) (Fig 5.1). After synthesis, the two
types of liposomes were characterized by size, polydispersity index (PDI), and surface
charge using DLS and M3-PALS at a concentration of 5 mM of liposomes. The mean
particle size of the CHOL-LPs was 114.9 ± 10.35 nm, while the mean size of the CHEMSLPs was slightly lower at 91.29 ± 7.66 nm (Fig. 5.2A-B). The PDI of the CHOL-LPs, 0.252,
was also higher than that of the CHEMS-LPs, 0.214 (Fig. 5.2C). Both values for PDI
indicated monodisperse liposomes in solution with minimal aggregation. The mean zetapotentials of the CHOL-LPs and CHEMS-LPs, +27.6 ± 1.79 mV and +23.2 ± 1.56 mV
respectively (Fig. 5.2C), were positive due to the cationic lipid component DOTAP and
the ability of CHEMS to be protonated in aqueous solution. Both liposome formulations
resulted in uniformly-sized, monodisperse, positively charged particles.
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5.2.2 Efficient Loading of Paclitaxel into Liposomes
In order to further compare the CHOL-LPs and CHEMS-LPs, the loading efficiency
of paclitaxel in the liposomes was analyzed. Paclitaxel was dissolved with the lipids and
rehydrated to form liposomes with a final drug concentration of 2.5 µg/mL. HPLC
analysis was used to determine the amount of paclitaxel loaded into each type of
liposomes, and the loading efficiencies of both types of liposomes were calculated. The
CHOL-LPs exhibited a loading efficiency of 80.4%, while the CHEMS-LPs loaded with an
efficiency of 79.3% (Table 5.1). Overall, the CHOL-LPs and CHEMS-LPs were comparable
in their ability to load paclitaxel.

5.2.3 Binding and Protection of siRNA in Liposomes
A gel shift assay was performed to examine the siRNA binding capabilities of the
CHOL-LPs and CHEMS-LPs. Samples of each liposome at concentrations of 5 mM and
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500 mM were examined. siRNA content was also examined after disruption with 0.1%
Triton X-100 in order to validate binding of siRNAs in liposomes. Intact and disrupted
liposomes at a concentration of 5 mM showed no stained siRNA, likely due to the siRNA
concentration being too dilute. Intact 500 mM CHOL-LPs and CHEMS-LPs stained for
siRNA inside of the wells, while both disrupted 500 mM liposome samples appeared
around the same area of the gel as free siRNA (Fig 5.3). Staining near the well in Lane 10
indicates remaining siRNA bound to liposome components. The disrupted 500 mM
CHOL-LPs showed more staining of siRNA than in the disrupted CHEMS-LPs; however,
the staining near the well in the disrupted CHEMS-LPs indicates incomplete release of
bound siRNA and further studies of the binding potential of CHOL- and CHEMS-LPs are
needed.
The amount of fluorescent non-targeting #5 siRNA bound to the liposomes was
quantified using fluorescence spectroscopy with a Biotek Synergy plate reader
containing a red (530/590) filter cube (Winooski, VT). The concentration of bound siRNA
was estimated using a standard curve of serial siRNA dilutions. A standard curve with
siRNA and Triton X-100 was also created to account for the interference of Triton X-100
in the fluorescence reading. Intact and disrupted samples of the CHOL-LPs and CHEMSLPs at a concentration of 500 mM were examined. The 5 mM samples were not
analyzed because the concentration of siRNA in the liposomes was too low to be
detected, as seen in the gel shift assay. Binding/loading efficiency, as determined by
siRNA concentration correlating to intensity of fluorescence, was higher in the CHOL-LPs
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than in the CHEMS-LPs (Table 5.2). Fluorescence quenching due to tight interactions
between protonated CHEMS and slightly negatively-charged DPPC in the lipid bilayer
may have influenced the apparent bound siRNA concentration.
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5.2.4 Cellular Uptake of Liposomes
CHOL-LPs mediated uptake of Nile Red and fluorescent non-targeting #5 siRNA
into OVCAR3-TR cells after 4- and 8-hour treatment with 50 µM of liposomes.
Fluorescence microscopy was used to visualize the intracellular accumulation of the
cholesterol-containing liposomes (Fig. 5.4). As the length of treatment increased, the
cellular uptake of the liposomes also increased, as demonstrated by the increase in red
fluorescence in the 8-hour treatment compared to the 4-hour treatment.
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Cellular uptake and co-localization of the CHOL-LPs and CHEMS-LPs loaded with
fluorescent siRNA was also examined in OVCAR3-TR cells using immunofluorescence.
The liposomes are expected to enter the cells through endocytosis due to incorporation
of cationic lipids and pegylation, so an early endosomal marker (EEA1) was used to label
endosome locations in the cell, as shown by green fluorescence. The CHOL-LPs
experienced increased cellular uptake compared to the CHEMS-LPs (Fig. 5.5). However,
final conclusions cannot be made about the uptake until further studies are done to
analyze the binding efficiency of siRNA in CHEMS-LPs without interference or quenching
from any of the lipids. Due to the lack of fluorescent labeling of the liposomes
themselves, our uptake visualization is based solely on the fluorescence of siRNA. Colocalization of the CHOL- and CHEMS-LPs with endosomes was analyzed using ImageJ.
Little co-localization was visualized in either liposomes (Fig. 5.6), indicating a different
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mechanism of cellular uptake than endocytosis, likely due to the ability of cationic lipids
to fuse and incorporate into the plasma membrane of cells.
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CHAPTER 6
DISCUSSION
In this study, we identified potential gene targets in the development of drugresistance in ovarian cancer cells. We developed two formulations of liposomes with the
ability to encapsulate paclitaxel and bind siRNAs for combinatorial delivery to drugresistant ovarian cancer cells. The concurrent delivery strategy provides the potential to
knockdown genes related to resistance and re-sensitize cells to paclitaxel to improve the
drug’s efficacy in resistant ovarian cancer cells. Also, liposomal delivery may allow for a
smaller effective drug dosage with limited systemic toxicity compared to standard
intravenous chemotherapy.
Our results identified potential gene targets involved in the development of
paclitaxel-resistance in ovarian cancer cells. Gene expression and microarray analysis
have been useful in discovering genes which might play a role in cisplatin-resistance in
ovarian cancer cells in vitro and in patient samples [100,101]. Similarly, paclitaxel
resistance has been studied through small-scale analysis of gene expression in multidrug
cross-resistance [102]. However, array analysis of gene expression in paclitaxel-resistant
ovarian cancer has yet to be explored on its own. The results of the siRNA
array/paclitaxel MTS assay demonstrated five different siRNAs significantly increased
anticancer effects upon transfection and paclitaxel treatment compared to paclitaxel
treatment alone. The identified gene targets, ABCB1, JAK2, and CFLAR, are related to
different functions in the cell, confirming the complexity of drug-resistance
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development and treatment. ABCB1, encodes for an efflux transporter which mediates
the efflux of chemotherapeutics in cells. JAK2 is a kinase in a signaling pathway
responsible for promoting cell proliferation and survival. CFLAR is a regulating protein
involved in the apoptosis pathways. This experiment validated the need to target
multiple pathways when treating drug-resistance in ovarian cancer. The three siRNAs
with the greatest anticancer effects have been chosen as therapeutic targets and will be
loaded into the liposomal delivery system in combination with paclitaxel in the future
for in vitro cytotoxicity studies.
After determination of gene targets, liposomes were synthesized. We
characterized the liposomes by evaluating size, polydispersity index, and surface charge
of the different formulations. The mean particle size of both formulations was about
100 nm and the PDI ranged from 0.214-0.252, indicating uniformly sized and
monodisperse particles. CHEMS-LPs possessed smaller mean particle size and PDI, likely
due to the presence of interactions with protonated CHEMS and DPPC creating tightlybound particles [103]. The zeta-potential of the liposomes ranged from +20 to +30 mV,
indicating stable, cationic particles due to the incorporation of cationic lipids and
protonation of CHEMS in aqueous media.
Paclitaxel loading efficiency and siRNA binding efficiency were analyzed after
initial characterization studies. Paclitaxel loading efficiency was almost identical in the
CHOL-LPs and CHEMS-LPs, with values of about 80%, indicating efficient drug loading
and encapsulation. siRNA binding did differ between the liposome formulations, with
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more siRNA binding shown in the CHOL-LPs than in the CHEMS-LPs. The difference in
siRNA concentration in the liposomes could be due to quenching of the fluorescent
siRNA in the CHEMS-LPs due to electrostatic interactions between CHEMS and DPPC. To
ensure proper binding of siRNA in the CHEMS-LPs, we would need to control the
formation of the liposomes and encourage the siRNA to bind inside, possibly by
introducing the siRNA into a system in which CHEMS is not protonated. The siRNA
binding could also be lower in the CHEMS-LPs, especially the disrupted samples, due to
formation of self-aggregates by CHEMS. These self-aggregates could be preventing the
release of siRNA during disruption, decreasing the apparent amount of siRNA. Further
RNA quantification studies can be done to eliminate the interference from the lipids.
Both of these theories are also validated through the gel shift assay because the
intact CHEMS-LPs sample demonstrated stained siRNA inside the well, indicating the
stain was able to reach the siRNA. Also, the CHEMS-LPs disrupted with Triton X-100
showed a fainter band of stained siRNA than the CHOL-LPs and staining of siRNA near
the well, showing some siRNA was still bound to lipid components even after disruption.
The gel shift assay indicated siRNA protection due to the lack of free siRNA present in
the intact liposomes. Further studies of siRNA binding ability in the CHEMS-LPs are
needed in order to create a potential pH-sensitive alternative to the CHOL-LPs. CHEMScontaining liposomes have not commonly been used for combination delivery systems,
though they are popular for single drug delivery systems. Thus, more extensive studies
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on the N/P ratios and charge ratios would be beneficial to increase siRNA binding
efficiency in the CHEMS-LPs.
Cellular uptake of Nile Red and fluorescent siRNA by drug-resistant ovarian
cancer cells was mediated by the cholesterol-containing liposomes in 4- and 8-hour
treatments. Uptake increased with increased treatment length. Immunofluorescence
was utilized to analyze cellular uptake and co-localization of the CHOL-LPs and CHEMSLPs loaded with fluorescent siRNA in endosomes after 2-hour treatments. The liposomes
mediated uptake in both treatments; however, greater uptake was visualized with the
CHOL-LPs than the CHEMS-LPs. The decrease in fluorescence from siRNA could be
correlated to the lower binding of siRNA in CHEMS-LPs than CHOL-LPs or due to
quenching and interference of lipids. Low amounts of co-localization of the fluorescent
siRNA in endosomes indicates an uptake mechanism other than endocytosis. By
fluorescently labeling the liposomes instead of only the loaded therapeutics, the uptake
of the liposomes can be visualized with fluorescence microscopy [104].
In order to determine the potential of the liposomes and selected siRNAs as an
effective therapy for drug-resistant ovarian cancer, studies examining the ability of the
liposomes to mediate silencing of the targeted siRNAs need to be conducted.
Quantification of gene targets in wild-type and resistant ovarian cancer cells can be
analyzed with western blotting and RT-PCR to ensure upregulation of genes in resistant
cells. Also, knockdown efficiency of the chosen siRNA and resulting viability can also be
explored. Cytotoxicity assays, including MTT assay, wound healing assay, and flow

60

cytometry for live/dead analysis, can help demonstrate the therapeutic potential of the
combination liposome delivery system.
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CHAPTER 7
CONCLUSION
Overall, we have identified three gene targets that may be involved in the
development of paclitaxel-resistance in ovarian cancer cells from a siRNA array. The
three siRNA with the greatest anticancer effects will be used as therapeutics in
combination with paclitaxel in our liposome delivery system. After liposome synthesis,
we confirmed uniform sizing, monodisperse particles, and stable cationic liposomes
through characterization studies. We demonstrated efficient loading of paclitaxel and
protection of bound siRNA in both liposome formulations. In addition, liposomes
mediated uptake of Nile Red and fluorescent siRNA or fluorescent siRNA alone into
ovarian cancer cells. The characterization studies of the liposomes indicate their
potential as a combination delivery system. However, further studies need to be done
to increase siRNA binding efficiency and examine the pH-sensitive release of CHEMSLPs. Also, in vitro and in vivo cytotoxicity studies are necessary to confirm the efficacy of
the combinatorial liposome delivery system.
Liposomal combination therapies are gaining popularity as potential treatments
for drug-resistant cancer. Combinatorial delivery can synergistically enhance the efficacy
of therapeutics when delivered to drug-resistant cells by simultaneously re-sensitizing
and treating cancer cells. The liposomes developed in this study show promise as
combination delivery systems upon optimizing siRNA binding and release profiles of the
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particles. We aim to create a more effective alternative to current treatments for drugresistant ovarian cancer and increase patient survival rates.

63

CHAPTER 8
FUTURE DIRECTIONS
In order to further determine the therapeutic potential of the developed
liposomal combination delivery systems, gene target expression, release profiles, and
cytotoxicity must be analyzed for both liposomes. Expression of the selected target
genes, ABCB1, JAK2, and CFLAR, must be studied in both wild-type and paclitaxelresistant ovarian cancer cells. Western blotting will be utilized to compare the
expression of the targeted genes in OVCAR3 and OVCAR3-TR ovarian cancer cells, where
upregulation of the gene targets in the OVCAR3-TR cells indicates a potential
involvement in paclitaxel-resistance. To further quantify the targeted genes in both cell
lines, reverse-transcription polymerase chain reaction (RT-PCR) will be used to
determine the RNA transcript levels.
After quantifying expression of gene targets in the OVCAR3 and OVCAR3-TR
ovarian cancer cells, siRNA knockdown will be used to determine the efficiency of the
siRNAs in silencing the selected genes. Western blotting and RT-PCR will be used to
quantify protein and RNA levels in untreated OVCAR3-TR cells and in cells transfected
with siRNAs correlating to targeted genes. The quantification of gene target expression
is vital in confirming the therapeutic potential of the selected siRNAs in targeting
mechanisms of paclitaxel-resistance.
To further characterize the CHOL- and CHEMS-LPs, release profile studies will be
completed to analyze the pH-sensitivity of CHEMS-LPs compared to CHOL-LPs. Release
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studies using release media of varying pHs will be used to determine the characteristics
of pH-responsive behavior in CHEMS-LPs in environments with similar pH to tumor
microenvironments. Other studies include scanning electron microscopy (SEM) and
conductivity studies of the liposomes in various pHs can be used to analyze the change
in shape and stability of the liposomes due to pH changes, indicating pH-sensitivity. In
addition, to improve siRNA quantification in the CHEMS-LPS, it is necessary to eliminate
interference or quenching due to the presence of lipids.
To quantify siRNA directly, a Take 3 microplate will be used in the Biotek Synergy
plate reader. Also, a Ribogreen assay, a method using an ultra-sensitive fluorescent
molecule to quantify small amounts of RNA without interference from lipids. If siRNA
quantification studies demonstrate lower siRNA binding/loading efficiencies in the
CHEMS-LPs, optimization of the size/charge ratio and N/P ratio of the liposomes will
take place.
Immunofluorescence will be done at a later time point, 4 hours, to examine
uptake mechanisms and track the localization and escape of both types of liposomes. To
better visualize the liposomes, liposomes will be fluorescently labeled instead of the
liposomal contents. A fluorescent tracker, like BODIPY FL or LysoTracker can then be
used to examine the mechanism of uptake of the liposomes.
Additional work on the synthesis methods of the liposomes will include
developing a method to improve stability of liposomes and a method of long-term
storage. Currently, synthesis of the liposomes is not optimal as liposomes are
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synthesized weekly, so developing a method of longer storage is needed. Synthesis of
liposomes will also expand to include targeting moieties and surface modifications to
increase specificity, cellular uptake, and intracellular release and accumulation.
Finally, cytotoxicity assays will be completed in vitro to examine the therapeutic
potential of the delivered siRNAs and paclitaxel, alone and in combination. Cell viability
assays, specifically MTT assays, will be used to determine viability of cells transfected
with siRNAs alone, treated with paclitaxel alone, or transfected and treated with siRNAs
and paclitaxel. The liposomal delivery systems will be analyzed to confirm the synergistic
anticancer effects of simultaneous siRNA knockdown and paclitaxel treatment. Wound
healing assays will be used to determine changes in motility of OVCAR3-TR ovarian
cancer cells after liposomal treatment. Flow cytometry will be used for live/dead
analysis of OVCAR3-TR cells treated with various concentrations of paclitaxel
encapsulated in liposomes. Western blotting and RT-PCR will be used to confirm the
knockdown of targeted genes after delivery of siRNAs by the liposomal delivery systems.
Through these future steps, the therapeutic potential of the liposomal delivery systems
as a combination therapy to combat paclitaxel-resistance in ovarian cancer.
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